IL2 and melanoma: Studies demonstrated that exosomes derived from engineered Jurkat T cells that expressed IL-2 on the surface downregulated PD-L1 levels in melanoma cells by reprogramming miRNA levels and suppressed tumour development in melanoma-bearing immunocompetent mice [200] (Fig. 5a).